GLP-1 Agonists Linked to Increased Wound Complications After Breast Reconstruction
Background
Free flap breast reconstruction is a complex surgical procedure often performed after mastectomy, involving transferring tissue from one part of the body to the breast area. GLP-1 receptor agonists (GLP-1 RAs), like semaglutide and liraglutide, are widely used medications for type 2 diabetes and obesity, known for their metabolic benefits. However, their impact on surgical outcomes, particularly wound healing in intricate procedures like free flap reconstruction, remains largely unexplored.
Results
The study revealed a statistically significant increase in overall wound complications among patients using GLP-1 RAs. Patients on GLP-1 RAs experienced a 2.5-fold higher incidence of major wound complications compared to the control group (35% vs. 14%, p<0.001). Specifically, the rate of flap necrosis (tissue death) was 3.1 times higher in the GLP-1 RA group (12% vs. 3.9%, p=0.002), requiring re-operation in 7% of these cases. Furthermore, surgical site infections were observed in 18% of GLP-1 RA users compared to 8% in controls (p=0.015), and dehiscence (wound separation) occurred in 15% versus 6% (p=0.008). These findings suggest a potential adverse effect of GLP-1 RA use on microvascular healing and overall wound integrity.
Why It Matters
This study highlights a critical safety consideration for patients undergoing free flap breast reconstruction who are also using GLP-1 RAs. The observed increase in serious wound complications, particularly flap necrosis, suggests that these medications may interfere with the delicate microvascular healing processes essential for successful flap survival. This information could lead to updated pre-operative guidelines recommending temporary cessation of GLP-1 RAs before elective reconstructive surgeries. Future prospective studies and mechanistic research are needed to confirm these findings and elucidate the underlying biological pathways involved, potentially leading to Phase II clinical trials.